{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"}],"units":"Participants"}],"description":"Severity of AEs was graded using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03","groups":[{"description":"All participants in this study received both study drugs and were therefore analysed together as a single treatment arm.\n\nParticipants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment.\n\nThe study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.","id":"OG000","title":"Acalabrutinib + Pembrolizumab"}],"paramType":"NUMBER","populationDescription":"All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the safety of the combination study treatment.","reportingStatus":"POSTED","timeFrame":"104 weeks","title":"Number of Participants With Grade 3-4 Adverse Events","type":"PRIMARY","unitOfMeasure":"Number of participants"}